SCA
CCXI

Secor Capital Advisors’s ChemoCentryx, Inc. CCXI Stock Holding History

Secor Capital Advisors’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12,798
Closed -$178K – 313
2019
Q1 		$178K Buy
+12,798
New +$146K 0.04% 372

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Secor Capital Advisors's CCXI Position: Q2 2019 in Review

Secor Capital Advisors sold out of ChemoCentryx, Inc. (CCXI) in Q2 2019, closing a stake of 12,798 shares — an estimated $178K sold.

Secor Capital Advisors first reported a position in CCXI in Q1 2019 and held it in 1 quarter. The position peaked at $178K in Q1 2019. 117 funds tracked by Wall St. Rank hold CCXI as of Q2 2019.

  • Secor Capital Advisors reported no remaining ChemoCentryx, Inc. position as of Q2 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 12,798 ChemoCentryx, Inc. shares in Q2 2019, an estimated $178K.
  • Secor Capital Advisors first reported a position in ChemoCentryx, Inc. in Q1 2019 and held it in 1 quarter.
  • Secor Capital Advisors's ChemoCentryx, Inc. position peaked at $178K in Q1 2019.
  • 117 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2019.

Based on Secor Capital Advisors's 13F filing for Q2 2019.